Vincerx Pharma, Inc.
VINC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | $0 | -$0 |
| % Margin | – | 50% | – | – |
| R&D Expenses | $1 | $3 | $4 | $4 |
| G&A Expenses | $2 | $6 | $4 | $4 |
| SG&A Expenses | $2 | $6 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $9 | $8 | $7 |
| Operating Income | -$3 | -$9 | -$8 | -$7 |
| % Margin | – | -826.4% | – | – |
| Other Income/Exp. Net | -$2 | $1 | -$0 | $6 |
| Pre-Tax Income | -$5 | -$8 | -$8 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$8 | -$8 | -$2 |
| % Margin | – | -748.5% | – | – |
| EPS | -0.96 | 4.22 | -1.41 | -0.32 |
| % Growth | -122.7% | 399.3% | -340.6% | – |
| EPS Diluted | -0.96 | 4.22 | -1.41 | -0.32 |
| Weighted Avg Shares Out | 5 | 5 | 6 | 6 |
| Weighted Avg Shares Out Dil | 5 | 5 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$9 | -$8 | -$7 |
| % Margin | – | -800.1% | – | – |